Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38658161 | 0.84 | MAPT (0.52) | HPGDTSHRMEN1KMT2AKDM4E | |
| SCHEMBL38658148 | 0.84 | MAPT (0.52) | HPGDTSHRMEN1KMT2AKDM4E | |
| SCHEMBL38658644 | 0.84 | MAPT (0.50) | HPGDMEN1KMT2ANPC1MAPT | |
| SCHEMBL28440558 | 0.82 | MAPT (0.42) | HPGDMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL19309852 | 0.81 | HPGD (0.51) | HPGDTSHRMEN1KMT2AKDM4E | |
| SCHEMBL2164171 | 0.81 | HPGD (0.38) | HPGDTSHRMEN1KMT2AKDM4E | |
| SCHEMBL28438847 | 0.81 | TDP1 (0.46) | HPGDMAPTTAS1R3TAS1R2ALDH1A1 | |
| SCHEMBL3184435 | 0.81 | TSHR (0.70) | HPGDTSHRMEN1KMT2AKDM4E | |
| SCHEMBL2643972 | 0.80 | TSHR (0.50) | HPGDTSHRKMT2AKDM4EMAPT | |
| SCHEMBL10921356 | 0.80 | TSHR (0.48) | HPGDTSHRMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242397-B1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1305301-B1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6608218-B2 | Such as 1-(cyclopentyloxy-(3,4-dichloro-phenyl)-acetyl)-3-methyl-urea for treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2003-08-19 | — | — | US | disclosed |
| EP-1305301-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-02 | — | — | EP | disclosed |
| US-20020198200-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-12-26 | — | — | US | disclosed |
| US-6486184-B2 | 1-(CYCLOPENTYLOXY-(3,4-DICHLORO- PHENYL)-ACETYL)-3-METHYL-UREA FOR EXAMPLE; USE IN TREATING HYPERGLYCEMIA CHARACTERISTIC OF ALL TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-11-26 | — | — | US | disclosed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-04-11 | — | — | US | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| WO-2002008209-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |
| US-4698333-A | Use of substituted malonic acid derivatives as agents for combating pests | BAYER AKTIENGESELLSCHAFT (DE) | 1987-10-06 | — | — | US | disclosed |
| EP-0076957-B1 | DIAMIDES OF SUBSTITUTED HYDROXYMALONIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PESTICIDES | BAYER AG (DE) | 1986-04-09 | — | — | EP | disclosed |
| EP-0108351-A2 | Use of substituted malonic-acid derivatives as pesticides | BAYER AG (DE) | 1984-05-16 | — | — | EP | disclosed |
| EP-0076957-A1 | Diamides of substituted hydroxymalonic acids, process for their preparation and their use as pesticides | BAYER AG (DE) | 1983-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | HPGD 1396/4885TSHR 3506/4885MEN1 4421/4885 |
| US-20020198200-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | HPGD 1297/4885TSHR 3583/4885MEN1 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.